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Fluvastatin Reverses Endothelial Dysfunction and Increased
Vascular Oxidative Stress in Rat Adjuvant-Induced Arthritis
Yoshisuke Haruna,1 Yoshitaka Morita,1 Toyotaka Yada,1 Minoru Satoh,1
David A. Fox,2 and Naoki Kashihara1
Objective. To investigate the effect of statins on
vascular dysfunction in rat adjuvant-induced arthritis
(AIA).
Methods. Fluvastatin (5 mg/kg/day) was adminis-
tered orally to rats with AIA, for 21 days after the onset
of arthritis. The vasodilatory response to acetylcholine
of aortic rings isolated from rats with AIA that were not
treated or were treated with fluvastatin and from nor-
mal rats was determined. The amounts of 4-hydroxy-2-
nonenal (HNE) and nitrotyrosine in aortas were mea-
sured by Western blotting. In vitro and in situ
superoxide production in aortas was evaluated based on
fluorogenic oxidation of dihydroethidium to ethidium.
Expression of NAD(P)H components and endothelial
nitric oxide synthase (eNOS) in aortas was examined by
real-time reverse transcriptase–polymerase chain reac-
tion and Western blotting. Serum levels of tetrahydro-
biopterin, a critical eNOS cofactor, were determined by
high-performance liquid chromatography.
Results. Fluvastatin reversed endothelial dysfunc-
tion in AIA without affecting the clinical severity of
arthritis or serum cholesterol concentration. Fluva-
statin reduced the amounts of HNE and nitrotyrosine in
the aorta, and the levels of superoxide expressed in
endothelial cells and smooth muscle cells in the tissue,
in rats with AIA. NADH- or L-arginine–induced super-
oxide production was not observed in the aortic samples
from fluvastatin-treated rats with AIA. Fluvastatin de-
creased the levels of expression of messenger RNA for
p22phox, a NAD(P)H oxidase component, in the aortas
of rats with AIA, but did not affect the expression of
eNOS. Serum levels of tetrahydrobiopterin were signif-
icantly reduced in rats with AIA, and were increased by
administration of fluvastatin.
Conclusion. Our findings demonstrate that fluva-
statin has potent vascular protective effects in AIA and
provide additional scientific rationale for the use of
statins to reduce cardiovascular mortality in patients
with rheumatoid arthritis.
Endothelial dysfunction, which represents the
earliest stage of atherosclerosis, has been observed in
patients with rheumatoid arthritis (RA) with high in-
flammatory activity, suggesting that this dysfunction
contributes to the increased cardiovascular mortality in
this disease (1–3). Although the pathophysiologic mech-
anism is not fully understood, mounting evidence of an
association between atherosclerosis and inflammation
suggests that systemic inflammation in RA may be
involved in the early stages of vascular damage (4–6).
We recently provided additional evidence to support this
hypothesis. We found that endothelial function is de-
pressed in rat adjuvant-induced arthritis (AIA), which
has been widely used as a model of RA (7). Reactive
oxygen species (ROS), which likely contribute to the
pathophysiology of endothelial dysfunction caused by
systemic inflammation, were found to be overproduced
in the aortas of rats with AIA (7). The study results
indicated that vascular damage in RA can be partially
modeled in animals and that it occurs early in the course
of disease. It prompted us to consider utilizing this
model as a tool to examine therapeutic options to
improve endothelial dysfunction caused by systemic in-
flammation.
One class of molecules that may improve vascular
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dysfunction is the statins, hydroxymethylglutaryl-
coenzyme A reductase inhibitors. Statins have been
demonstrated to reduce both cardiovascular morbidity
and mortality (8–10). It has been shown that hypercho-
lesterolemia impairs endothelial function, which is re-
stored by statin treatment (11–13). Although the bene-
ficial effect generally has been attributed to the
decrement in plasma cholesterol levels, much evidence
suggests that statins exert effects that are independent of
cholesterol-lowering actions. Statins restore endothelial
function before serum cholesterol levels have been
significantly reduced (14). It is reported that statins
up-regulate expression of endothelial nitric oxide syn-
thase (eNOS), which is a key enzyme in the synthesis of
vascular NO, a major endothelium-dependent vasodila-
tor (15,16). Furthermore, statins induce the phosphory-
lation and activation of eNOS via the protein kinase Akt
pathway (17). Statins have also been shown to have
antioxidant effects. They inhibit angiotensin II–induced
free radical production by vascular smooth muscle cells
in vitro and reduce aortic superoxide (O2
) production
in hypertensive rats (18).
It has recently been demonstrated that statins
have various antiinflammatory and immunomodulatory
effects, and the unique properties of statins have moti-
vated rheumatologists to study this drug for the treat-
ment of arthritis (19). In a randomized placebo-
controlled study, RA patients who received atorvastatin
exhibited a modest, but statistically significant, improve-
ment in their arthritis (20).
In the present study, we administered fluvastatin
to rats with AIA. We were especially interested in the
effects of statins on endothelial dysfunction and vascular
oxidative stress in AIA. We found that fluvastatin re-
versed the endothelial dysfunction in AIA without af-
fecting the clinical severity of arthritis. The increased
vascular oxidative stress in AIA was also reversed by
treament with fluvastatin. To our knowledge, this is the
first reported study to evaluate the effects of statins on
endothelial dysfunction in an autoimmune and inflam-
matory disease model.
MATERIALS AND METHODS
Induction and treatment of rat AIA. Six-week-old male
Lewis rats were obtained from Charles River Japan (Kana-
gawa, Japan). Freund’s complete adjuvant was prepared by
suspending heat-killed Mycobacterium butyricum (Difco, De-
troit, MI) in mineral oil at 10 mg/ml. Rats were injected
intradermally with 100 l of the adjuvant at the base of the tail.
Arthritis developed by day 10 post–adjuvant injection. Rats
with AIA were subsequently left untreated or were adminis-
tered 5 mg/kg of fluvastatin (Tanabe Pharmaceutical, Osaka,
Japan) dissolved in drinking water, daily for 21 days after the
onset of arthritis. Limbs were individually scored every other
day on a scale of 0–3 (maximum possible score 12). Scores
were assigned based on the amount of erythema, swelling, or
joint rigidity in each limb. Systolic arterial blood pressure was
measured by the tail cuff method with a pulse transducer
(model BP98-A; Softron, Tokyo, Japan). Twenty-one days
after the onset of arthritis, rats were killed and thoracic aortas
and serum samples were isolated for further experiments. Mice
without AIA were studied as normal controls. All procedures
were performed in accordance with our institutional guidelines
for animal research.
Endothelium-dependent vascular responses in rat
AIA. The thoracic aorta was dissected and cut into 3.0-mm
rings that were set up in organ baths. Endothelial vascular
function was evaluated as described previously (7).
Western immunoblotting. Expression of 4-hydroxy-2-
nonenal (HNE)–modified proteins, nitrotyrosine, and eNOS
in isolated aortas was assessed by Western blotting, as de-
scribed previously (7,21). Antiactin was used for normaliza-
tion.
Fluorescence spectrometric assay of O2
 production
in isolated aortas. O2
 production in homogenates of isolated
aortas was detected based on dihydroethidium conversion to
ethidium as described previously (7,22), after addition of
various substrates for O2
-producing enzymes and their inhib-
itors. The substrates or inhibitors used in this study were
NADH (0.1 mM), diphenylene iodonium chloride (0.1 mM),
L-arginine (1 mM), and tetrahydrobiopterin (BH4, 0.01 mM)
(all from Sigma-Aldrich, Tokyo, Japan).
In situ O2
 measurement by confocal fluorescence
microscopy. The oxidative fluorescent indicator dihydro-
ethidium was used to evaluate in situ O2
 generation. Briefly,
fresh aortic rings embedded in OCT compound were cut into
20-m–thick sections, submerged in 2 M dihydroethidium
(Sigma-Aldrich) in phosphate buffered saline (PBS), and
incubated for 30 minutes at 37°C. At the end of this incubation
period, the slides were washed with PBS and kept at 4°C.
Fluorescence was detected using a laser scanning confocal
microscope (TCS-NT; Leica Microsystems, Tokyo, Japan) with
a 585-nm long-pass filter.
RNA isolation and real-time quantitative reverse
transcriptase–polymerase chain reaction (RT-PCR). Total cel-
lular RNA was extracted with TRIzol by a single-step method.
RT-PCR was performed using a Ready-To-Go T-Primed
First-Strand Kit (Amersham Biosciences, Tokyo, Japan) for
first-strand complementary DNA (cDNA) synthesis. Real-time
quantitative PCR was performed using an ABI Prism 7700
sequence detection system (Applied Biosystems, Foster City,
CA). The sequences of primers and probes used for p22phox,
p47phox, gp91phox (phox indicates phagocyte oxidase), and
eNOS have been described previously (22,23). Complementary
DNA from serially diluted samples was amplified using Premix
Ex Taq (Takara Bio, Shiga, Japan). The threshold cycle is the
PCR cycle at which an increase in the fluorescent emission
above the baseline signal is first detected. Since the values of
the threshold cycle decrease proportionally with increased
target quantity, they were used to determine the relative
cDNA amounts in each sample and to evaluate levels of
p22phox, p47phox, gp91phox, and eNOS messenger RNA
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(mRNA), which were normalized to the quantity of GAPDH
mRNA as described previously (24).
Measurement of fluvastatin, adiponectin, and BH4.
Serum samples were collected 21 days after the onset of
arthritis in rats with AIA that were left untreated or treated
with fluvastatin and from normal rats. Serum concentrations of
fluvastatin were measured by high-performance liquid chroma-
tography (HPLC) (25) at Tanabe R&D Service (Osaka, Ja-
pan). Serum levels of adiponectin were determined by quan-
titative sandwich enzyme-linked immunosorbent assay (Otsuka
Pharmaceutical, Tokushima, Japan). Concentrations of BH4 in
serum were determined by HPLC as described elsewhere
(26,27). Briefly, serum samples were mixed 1:1 with a solution
of 0.5M perchloric acid containing 0.1 mM Na2-EDTA and 0.1
mM Na2S2O3 for protein separation. After filtration, BH4
concentrations in the samples were measured by HPLC. BH4
was detected fluorometrically at wavelengths of 350 nm for
excitation and 440 nm for emission, by postcolumn NaNO2
oxidation with a reverse-phase ion-pair LC system (LC-10
series; Shimadzu, Kyoto, Japan).
Statistical analysis. Data were expressed as the
mean  SEM. The Mann-Whitney U test was used to compare
group means. P values less than 0.05 were considered signifi-
cant.
RESULTS
Fluvastatin-induced reversal of endothelial dys-
function in AIA. We first evaluated endothelium-
dependent vasodilatory responses in rats with AIA that
were left untreated or treated with fluvastatin. Consis-
tent with findings in our previous study (7), the
endothelium-dependent relaxation of the aortic ring was
significantly depressed in rats with AIA compared with
that in normal rats. We further found in the present
study that administration of fluvastatin reversed the
endothelial dysfunction in AIA (Figure 1).
Physical and metabolic features of the rats 21
days after arthritis onset are summarized in Table 1. Of
note, despite the apparent vascular protective effect,
fluvastatin did not affect the severity of clinical arthritis
during the course of disease. The mean body weight of
untreated rats with AIA was 83% of that in control rats,
Figure 1. Effect of fluvastatin (Flu) on endothelial dysfunction in rat
adjuvant-induced arthritis (AIA). Thoracic aortic rings were prepared
from the aortas of rats with AIA that were left untreated, rats with
AIA that were treated with fluvastatin at 5 mg/kg/day administered
orally for 21 days after the onset of arthritis, and normal control rats
(Cont) (n  6 per group). Norepinephrine was applied to achieve
near-maximal contraction, and responses to acetylcholine at the
indicated concentrations were determined. Relaxation was expressed
as the percent of the precontraction tension induced by norepineph-
rine. Values are the mean  SEM.   P  0.05;   P  0.01, versus
normal rats.
Table 1. Physical and metabolic features of the rats*
Normal AIA, untreated AIA, fluvastatin-treated
Weight, gm 328  8 273  6† 239  4†
Arthritis score 0 11.5  0.3 11.8  0.3
Systolic blood pressure, mm Hg 112  5 105  2 109  2
Total cholesterol, mg/dl 89.0  1.5 83.0  1.7 90.7  2.4
Triglycerides, mg/dl 139.0  13.9 89.0  6.7† 71.2  6.7†
Aspartate aminotransferase, IU/liter 86.7  13.4 70.2  4.0 73.4  4.8
Alanine aminotransferase, IU/liter 25.3  1.6 18.8  0.9 23.8  2.7
Adiponectin, g/ml 10.8  11.0 6.3  0.5† 10.2  0.6‡
Tetrahydrobiopterin, ng/ml 2.3  0.2 1.5  0.2† 3.1  0.3‡
* Rats with adjuvant-induced arthritis (AIA) were left untreated or were administered fluvastatin at 5
mg/kg/day orally for 21 days after arthritis onset. Arthritis score was determined as described in Materials
and Methods; serum concentrations of adiponectin and tetrahydrobiopterin were determined by
enzyme-linked immunosorbent assay and high-performance liquid chromatography, respectively. Values
are the mean  SEM (6 rats per group).
† P  0.01 versus normal rats.
‡ P  0.05 versus untreated rats with AIA.
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and this was not affected by treatment with fluvastatin.
There was no difference between normal rats, untreated
rats with AIA, and fluvastatin-treated rats with AIA in
terms of blood pressure, serum total cholesterol levels,
and liver enzyme levels. The serum triglyceride level was
significantly lower in untreated rats with AIA than in
normal rats, and this was not affected by fluvastatin
treatment. Interestingly, serum levels of adiponectin, an
antiatherogenic protein (28), were significantly reduced
in untreated rats with AIA (P  0.01 versus normal rats),
and were increased by administration of fluvastatin (P 
0.05 versus untreated rats with AIA). The mean  SEM
serum concentration of fluvastatin in rats with AIA that
were administered the drug (n  6) was 76.8  13.0
ng/ml.
Effect of fluvastatin on enhanced oxidative stress
in the aortas of rats with AIA. We next examined
whether fluvastatin affects vascular oxidative stress in
AIA. Western blot analysis revealed that the amounts of
HNE-modified or nitrotyrosine-containing proteins, in-
dicators of oxidative stress, were significantly increased
(P  0.01) in the aortas of rats with AIA compared with
those of normal rats. We found that fluvastatin signifi-
cantly (P  0.05) reduced the amounts of HNE-
modified proteins (1.19-fold increase over normal, ver-
sus 2.73-fold in rats with AIA that were not treated with
fluvastatin) (Figure 2A) and nitrotyrosine-containing
proteins (1.29-fold increase over normal, versus 1.82-
fold in rats with AIA not treated with fluvastatin)
Figure 2. Reduction of oxidative stress in the aortas of rats with AIA
treated with fluvastatin. A and B, Western blot analyses of oxidatively
modified proteins containing 4-hydroxy-2-nonenal (A) and proteins
containing nitrotyrosine (B) in aortas isolated from normal control rats
and rats with AIA that were left untreated or treated with fluvastatin
(n  6 per group). Representative blots are shown. The bands were
normalized to the quantity of actin protein, using NIH image analysis
software. Quantitative values (relative to control) were determined
and are shown as the mean and SEM.   P  0.01 versus normal rats;
#  P  0.05 versus untreated rats with AIA. C, Superoxide (O2
)
production in aortic tissue from a normal control rat, an untreated rat
with AIA, and a fluvastatin-treated rat with AIA. In situ O2
 gener-
ation was evaluated based on fluorogenic oxidation of dihydroethidium
to ethidium and imaged by confocal laser scanning microscopy (orig-
inal magnification  200). See Figure 1 for definitions.
Figure 3. Fluvastatin-induced reduction in the activity of NAD(P)H
oxidase and nitric oxide synthase, which are responsible for superoxide
(O2
) production in the aorta of rats with AIA. Homogenates of
aortas from normal control rats, untreated rats with AIA, and
fluvastatin-treated rats with AIA were incubated with NADH or
L-arginine, and O2
 production was measured by fluorogenic oxidation
of dihydroethidium (DHE) to ethidium. Diphenylene iodonium chlo-
ride (DPI) was added to inhibit NAD(P)H oxidase. The effect of
tetrahydrobiopterin (BH4) on L-arginine–induced O2
 production was
also examined. Values are the mean and SEM (n  4 rats per group)
and are expressed relative to values in normal controls.   P  0.05
versus normal control rat aortas; #  P  0.05 versus aortas from
untreated rats with AIA incubated with NADH; ##  P  0.05 versus
aortas from untreated rats with AIA incubated with L-arginine. See
Figure 1 for other definitions.
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(Figure 2B). Vascular O2
– production was evaluated
based on dihydroethidium conversion to ethidium and
imaged by confocal laser-scanning microscopy (Figure
2C). The results revealed that O2
– was highly expressed
in endothelial cells as well as smooth muscle cells in
aortic tissue of rats with AIA. Fluvastatin was found to
decrease the levels of O2
– expressed in both cell types in
the tissue.
Fluvastatin-induced inhibition of NAD(P)H oxi-
dase in the aortas of rats with AIA. To examine the
mechanisms underlying the decreased vascular ROS
production in rats with AIA treated with fluvastatin, we
assessed the activity and expression of NAD(P)H oxi-
dases. First, homogenates of the isolated aortas were
incubated with or without NADH, and O2
 production
was measured by fluorescence spectrometric assay (Fig-
ure 3). In accordance with the data shown in Figure 2,
spontaneous production of O2
 was significantly (P 
0.05) greater in the aortas of rats with AIA than in those
of normal rats, whereas this increase was not observed in
the aortas of rats with AIA treated with fluvastatin.
Incubation of aortas of rats with AIA with NADH
resulted in a significant increase in O2
– production
compared with that in aortas incubated without sub-
strate (P  0.05). The NADH-induced increase in O2
–
production was not observed in the samples from rats
with AIA treated with fluvastatin. These results indicate
that functional activity of NAD(P)H oxidase in the
aortas of rats with AIA was inhibited by fluvastatin
treatment.
NAD(P)H oxidase is a multicomponent enzyme.
We investigated levels of expression of mRNA for
NAD(P)H oxidase components in rat aortas, by real-
time RT-PCR (Figure 4). The membrane-associated
components p22phox and gp91phox and the cytosolic
component p47phox (29) were examined. Expression of
mRNA for all NAD(P)H oxidase components was sig-
nificantly higher (P  0.05 for each) in the aortas of rats
with AIA than in normal rat aortas. Administration of
fluvastatin to rats with AIA significantly (P  0.05)
reduced the level of expression of p22phox mRNA
(1.7-fold increase over the level in normal rats, versus
6.9-fold increase in untreated rats with AIA). Expression
of gp91phox and p47phox mRNA in the aortas of rats
with AIA tended to be decreased by treatment with
fluvastatin, but the reductions were not statistically
significant (for gp91phox, 1.9-fold increase over normal
in fluvastatin-treated rats with AIA versus 3.7-fold in
untreated rats with AIA; for p47phox, 4.0-fold increase
in fluvastatin-treated rats with AIA versus 5.9-fold in
untreated rats with AIA).
Fluvastatin-induced amelioration of eNOS dys-
function in the aortas of rats with AIA. Another impor-
tant source of vascular O2
 excess in AIA is eNOS (7).
Consistent with results in our previous study (7), we
found in the present study that both mRNA and protein
levels of eNOS in the aortas of rats with AIA were
higher (P  0.05) than levels in normal rat aortas
(Figure 5). Fluvastatin did not affect either mRNA or
protein expression of eNOS in the aortas of rats with
AIA (Figure 5).
When homogenates of aortas from fluvastatin-
treated rats with AIA were incubated with L-arginine, a
substrate of eNOS, there was no increase in O2
– produc-
tion (Figure 3). These results suggest that eNOS dys-
function in the aortas of rats with AIA is ameliorated by
fluvastatin. We measured serum levels of BH4, an essen-
tial cofactor of eNOS, in each group, by HPLC. As
shown in Table 1, serum BH4 levels in rats with AIA
Figure 4. Expression of mRNA for NAD(P)H oxidase components in
aortas from normal control rats, untreated rats with AIA, and
fluvastatin-treated rats with AIA. Real-time reverse transcriptase–
polymerase chain reaction was performed as described in Materials
and Methods. Levels of the membrane-associated p22phox and
gp91phox components and the cytosolic p47phox component were
normalized to the GAPDH mRNA level. Values are the mean and
SEM (n  5 rats per group) and are expressed relative to values in
normal controls.   P  0.05 versus normal control rat aortas; # 
P  0.05 versus aortas from untreated rats with AIA. See Figure 1 for
definitions.
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were significantly (P  0.01) lower than those in normal
rats. Of interest, serum BH4 levels were increased by
administration of fluvastatin (P  0.05).
DISCUSSION
RA is associated with increased mortality due to
cardiovascular events (30–33). The frequency of carotid
atherosclerosis has been shown to be increased among
patients with RA independent of traditional risk factors
(34), although the precise mechanism remains unknown.
Further studies are needed to identify interventional
strategies that will prevent the development of clinical
cardiovascular diseases in RA patients. Statins are a
promising class of drug for this purpose. However,
clinical or basic science evidence of the protective effect
of statins against vascular damage in RA is currently
very limited. In a randomized double-blind placebo-
controlled study, 4-week treatment with simvastatin was
shown to improve endothelial function in patients with
active RA, without affecting systemic inflammation or
clinical arthritis (35).
To our knowledge, no basic science study on the
effect of statins on vascular damage in animal models of
RA has been reported previously. In the current study,
we demonstrated that oral treatment with fluvastatin
reverses endothelial dysfunction in rat AIA. This effect
is accompanied by decreased ROS production in the
aorta. Our results may provide insight into the basis of
the effects of statins on vascular functions, and an
additional scientific rationale for using these drugs to
reduce cardiovascular mortality in patients with RA. We
selected a 5-mg/kg daily dosage of fluvastatin because
5–10 mg/kg of this drug does not affect serum lipid levels
in other disease models in rats (36–38). Indeed, levels of
serum lipids were not changed by treatment with fluva-
statin in our arthritis model.
Although it is now well recognized that statins
have antiinflammatory and immunomodulatory effects
(19), fluvastatin at 5 mg/kg/day in the present study
exerted no influence on the clinical severity of arthritis
or body weight in rat AIA. To examine whether other
compounds of the statin family suppress arthritis, we
have administered pravastatin (10 mg/kg/day) or pitavas-
tatin (3 mg/kg/day) to rats with AIA, and no significant
effects were observed (Haruna Y, Morita Y: unpub-
lished observations). A limited number of animal studies
have investigated whether statins exert antiarthritic ef-
fects. In murine collagen-induced arthritis, simvastatin
administered intraperitoneally at a daily dosage of 40
mg/kg was shown to suppress arthritis, whereas lower
doses of this drug had no significant effect (10 or 20
mg/kg/day) (39). A more recent study showed no pre-
ventive or curative effects of atorvastatin, rosuvastatin,
or simvastatin in murine collagen-induced arthritis (40).
In a rat model of AIA, atorvastatin administered orally
at a daily dosage of 1–10 mg/kg was shown to inhibit
arthritis (41).
These discrepancies could be explained by the
differences in models, drugs, and doses. Our results
suggest that the vascular protective effect of statins in
the arthritis model can be independent of antiarthritic or
cholesterol-lowering effects, and may occur with the use
of lower doses.
NAD(P)H oxidases have been shown to have a
Figure 5. Lack of effect of fluvastatin on levels of expression of
endothelial nitric oxide synthase (eNOS) in aortas of rats with AIA. A,
Endothelial NOS mRNA expression in isolated aortas. Real-time
reverse transcriptase–polymerase chain reaction was performed as
described in Materials and Methods. Levels of eNOS were normalized
to the GAPDH mRNA level. Values are the mean and SEM (n  5
rats per group) and are expressed relative to values in normal controls.
  P  0.05 versus normal control rat aortas. B, Western blot analysis
of eNOS in isolated aortas. Representative blots are shown. Densito-
metric quantification of the corresponding bands was performed using
NIH image analysis software. Quantitative values (relative to control)
are shown as the mean and SEM (n  6 rats per group).   P  0.01
versus normal control rat aortas. See Figure 1 for other definitions.
1832 HARUNA ET AL
major role in oxidative excess in the vasculature (27,42).
In rat AIA, NAD(P)H oxidases are responsible for
vascular overproduction of O2
 (7). We showed in the
present study that fluvastatin inhibits activity of vascular
NAD(P)H oxidases in AIA. Levels of expression of
mRNA for p22phox, a membrane-associated component
of NAD(P)H oxidase, were found to be decreased by
treatment with fluvastatin. It has been demonstrated
that modulation of p22phox expression is closely con-
nected with NAD(P)H oxidase activity (43,44). The
inhibitory effect of statins on the expression of
NAD(P)H oxidase components has been shown in other
atherogenic conditions. Treatment with atorvastatin re-
duces vascular expression of p22phox mRNA in sponta-
neously hypertensive rats (45). Our results indicate that
the down-regulation of vascular NAD(P)H oxidases by
fluvastatin contributes to the decreased ROS production
in the vasculature in this arthritis model.
Previously, we found that eNOS expression in the
aortas of rats with AIA is increased at the mRNA and
protein levels, and this enzyme also contributes to
vascular ROS production (7). Since statins have been
described to up-regulate eNOS expression by stabilizing
its mRNA (15,16), we investigated whether fluvastatin
alters expression of eNOS in the aorta in AIA. The data
revealed that fluvastatin does not affect eNOS levels in
AIA. However, it was also shown that L-arginine does
not induce an increase in O2
 in isolated aortas from
fluvastatin-treated rats with AIA. These results suggest
that fluvastatin alters the functional nature of vascular
eNOS in rats with AIA.
Of note, serum levels of BH4, an essential cofac-
tor of eNOS, were increased upon administration of
fluvastatin. Deficiency of BH4 due to impaired synthesis
or increased catabolism is known to be associated with
the formation of uncoupled, dysfunctional eNOS, con-
tributing to generation of O2
 instead of NO (46,47).
Treatment of AIA with BH4 was previously shown to
reverse the endothelial dysfunction (7). We thus specu-
late that the decrease in vascular ROS production in
AIA due to treatment with fluvastatin results in in-
creased BH4 availability, leading to the prevention of
formation of the uncoupled form of eNOS.
Another interesting observation in the present
study was that serum levels of adiponectin, an adipocyte-
specific secretory protein, were increased in rats with
AIA that were treated with fluvastatin. Since body
weight was not affected by the treatment, we conclude
that fluvastatin alters adiponectin levels independent of
adiposity.
There is accumulating evidence suggesting that
adiponectin has antiatherogenic properties. Reduced
adiponectin levels are reported to be linked to develop-
ment of insulin resistance and increased risk of coronary
artery disease (48,49). Hypoadiponectinemia in hyper-
tensive patients has been shown to be associated with
endothelial dysfunction (50). Moreover, endothelium-
dependent vasodilation is impaired in adiponectin-
knockout mice (50). It has also been demonstrated that
adiponectin stimulates in vitro production of NO in
vascular endothelial cells (51). Thus, the fluvastatin-
induced increase in adiponectin levels may in part
mediate the improved endothelial function in AIA.
Elevated adiponectin levels in the circulation have been
shown to suppress the development of atherosclerosis in
apolipoprotein E–knockout mice (52). Although the
mechanism by which statins increase adiponectin levels
remains unclear, this effect could be another benefit of
use of statins to protect vascular function.
The finding of early vascular dysfunction in rats
with AIA is consistent with a previous report (53) that
the risk of coronary heart disease in RA patients pre-
cedes fulfillment of the American College of Rheuma-
tology (formerly, the American Rheumatism Associa-
tion) criteria for RA (54). Physicians who care for RA
patients should be aware of the increased risk of cardio-
vascular disease in these patients. The present study
demonstrates that fluvastatin has potent vascular protec-
tive effects in an animal model of RA. Statins may have
clinical benefit beyond lipid lowering in improving en-
dothelial function in RA patients (35). However, sup-
porting data from large clinical trials are needed before
statin therapy for RA can be recommended.
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